<DOC>
	<DOCNO>NCT00402428</DOCNO>
	<brief_summary>This phase 3 , randomize , multi-center study evaluate efficacy safety albumin interferon alfa 2b ( alb-IFN ) combination ribavirin compare peginterferon alfa-2a ( PEGASYS PEG-IFNa2a ) combination ribavirin subject chronic hepatitis C , genotype 1 IFNa treatment naive .</brief_summary>
	<brief_title>Efficacy Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin IFN Naive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Key Diagnosis chronic hepatitis C. Liver biopsy perform within 2 year Day 0 screening . Infected hepatitis C virus genotype 1 . Interferon alfa treatment na√Øve ( ie , never treat interferon product ) . Subjects eligible enter study ( partner ) pregnant nursing , sterile , non childbearing potential , willing practice abstinence use appropriate birth control method study 7 month last dose ribavirin . Have compensate liver disease . Key Decompensated liver disease include subject past history presence ascites , bleed varix hepatic encephalopathy . History moderate , severe uncontrolled psychiatric disease , especially depression , include history hospitalization prior suicidal attempt . Positive human immunodeficiency virus ( HIV1 ) hepatitis B surface antigen ( HBsAG ) . Clinical diagnosis cause chronic liver disease include limited hepatitis B , autoimmune hepatitis , primary biliary cirrhosis , alcoholic liver disease , hemochromatosis , Wilson 's Disease , alpha 1antitrypsin deficiency . A history immunologically mediate disease ( eg , rheumatoid arthritis , inflammatory bowel disease , moderate/severe psoriasis , sarcoidosis , systemic lupus erythematosus ) . Active seizure disorder within last 2 year . Organ transplant cornea hair transplant . Clinically significant hemoglobinopathy ( eg , thalassemia , sickle cell anemia ) . Cancer within last 5 year ( exception adequately treat basal cell carcinoma skin situ carcinoma uterine cervix ) . Drug alcohol addiction within last 6 month . Subjects supervise methadone treatment program may enrol study . Received experimental agent within 28 day prior Day 0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>CHC</keyword>
	<keyword>HepC</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>HCV</keyword>
</DOC>